Diabetic Nephropathy 1


Published on

Published in: Health & Medicine, Travel
No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Diabetic Nephropathy 1

  1. 1. Diabetic Nephropathy Dr Mohamed Alamin Nephrology and Renal Transplant Specialist KAAH & OC Jiddah KSA
  2. 2. بسم الله الرحمن الرحيم
  3. 3. Diabetic Nephropathy <ul><li>Major Microvascular Complication of diabetes. </li></ul><ul><li>Leading Cause Of ESRD in Many Countries. </li></ul><ul><li>Leading Cause Of CVS Morbidity& Mortality. (20- to 40-fold increased risk for CV mortality) . </li></ul><ul><li>Independent Risk Factor for Hospitalization </li></ul><ul><li>Alarming increase % of ESRD pts. Caused by DM (in US from 27% in 1982, 36% in 92, 43% in 99 and 45% in 04). USRDS. ADR 2006 </li></ul><ul><li>Not all diabetic Pts will develop DN (only ~ 40%) </li></ul>
  4. 4. <ul><li>United States: From 2000 – 2004 Total ESRD Patients = 497, 934 DM = 220,929 = 44.9% Type 1 = 19,136 Type 2 = 201,739 </li></ul>Diabetic Nephropathy
  5. 5. Diabetic Nephropathy USRDS 2006
  6. 6. Diabetic Nephropathy Saudi Arabia 2006
  7. 7. DN: Diagnosis What are the Diagnostic Criteria ? Who are the Susceptible Patients ?
  8. 8. DN: Diagnosis What are the Diagnostic Criteria ? Who are the Susceptible Patients ?
  9. 9. <ul><li>Genetic risk factors </li></ul><ul><ul><li>Familial history of HTN (1 st degree relatives) </li></ul></ul><ul><ul><li>Familial history of cardiovascular events (1 st degree relatives) </li></ul></ul><ul><ul><li>Racial variation: DN is more prevalent among African Americans, Asians, and Native Americans than Caucasians . </li></ul></ul><ul><li>Hypertension </li></ul><ul><ul><li>Small increase in systemic BP, within the normal range, at onset of diabetes is already important for the initiation of diabetic nephropathy. </li></ul></ul><ul><ul><li>Hovind P et al. (2004). Br Med J 328:1105 </li></ul></ul><ul><ul><li>Change in diurnal variation in blood pressure with loss of nocturnal dipping could be observed prior to the development of microalbuminuria. </li></ul></ul><ul><ul><li>Daneman D et al (1994) Kidney Int 46:1154–1159 </li></ul></ul><ul><li>Poor glycemic control: Sustained hyperglycemia HbA1c > 8.6. </li></ul><ul><li>Retinopathy </li></ul><ul><li>Dyslipidemia </li></ul><ul><li>Smoking </li></ul>DN: Susceptibility / Risk Factors
  10. 10. |} <ul><li>Protein Overload: </li></ul><ul><ul><li>With protein intakes greater than 20% of energy intake there is an association between protein with increased albumin excretion rate. </li></ul></ul><ul><ul><li>Marion J et al. Current Diabetes Reports 2003, 3:412-417 </li></ul></ul><ul><li>Slightly Elevated UAE: at onset of diabetes already predicted the development of MA. </li></ul><ul><ul><li>the risk of progression from normoalbuminuria to microalbuminuria and macroalbuminuria within 10 years was 70% if the patient had a combination of four risk factors, namely, retinopathy, urinary AER>10 mg/24 h, HbA1c>8.6% and smoking, as against only 10% risk of progression if none of these risk factors were present. </li></ul></ul><ul><ul><li>Rossing P et al. (2002). Diabetes Care 25: 859–864 . </li></ul></ul>DN: Susceptibility / Risk Factors
  11. 11. <ul><li>Low Birthweight: </li></ul><ul><ul><li>is related to initiation of microalbuminuria and the presence of diabetic nephropathy. </li></ul></ul><ul><ul><li>Hovind P et al. (2004). Br Med J 328:1105 </li></ul></ul><ul><li>Oral Contraceptive : activate RAS and increase risk of developing DN. </li></ul><ul><li>Ahmed SB et al (2005). Diabetes Care 28:1988–1994. </li></ul><ul><li>Cardiovascular Risk Markers </li></ul>DN: Susceptibility / Risk Factors
  12. 12. Diabetic Patient IN Development Of In The Presence Of Diabetic Retinopathy Hypertension Progressive Renal Deterioration Absence of other causes P ersistant Proteinuria > 300 mg / day DN: Diagnostic Criteria Type 1> 10 Y Type 2 at Diagnosis
  13. 13. 1. Duration of Diabetes in DN Average Type 1: Overt DN Rarely occur before 10 yrs. Type 2: May be present in newly diagnosed patients . Peak Peak incidence  10 to 20 y duration If duration > 30 y + Normoalbuminuria Risk is Very Low DN: Diagnostic Criteria Decline After 20 y  Progressive decline in incidence takes place.
  14. 14. Normal Protein in urine should not exceed 150 mg /day 2. Abnormal Urinary Albumin Excretion DN: Diagnostic Criteria
  15. 15. <ul><li>This 150 mg /day is composed of: </li></ul><ul><li>Tamm Horsfall Protein 70 mg </li></ul><ul><li>Protein of Blood group 35 mg </li></ul><ul><li>Albumin (0-30mg) </li></ul><ul><li>Others (enzymes, hormones, </li></ul><ul><li>immunoglobulin ….etc) 29mg </li></ul>2. Abnormal Urinary Albumin Excretion DN: Diagnostic Criteria
  16. 16. The structural damage in DN leads to Albumin in urine = Albuminuria 2. Abnormal Urinary Albumin Excretion DN: Diagnostic Criteria
  17. 17. <ul><li>Normoalbuminuria < 30 mg/day </li></ul><ul><li>Microalbuminuria 30 - 300 mg / day </li></ul><ul><li>Macroalbuminuria > 300 mg / day </li></ul>2. Abnormal Urinary Albumin Excretion DN: Diagnostic Criteria
  18. 18. <ul><li>All or at least 80% of patients with nephropathy have retinopathy. </li></ul><ul><li>Brenner and Rector. The Kidney: 1742-1743. 2000 </li></ul><ul><ul><li>American Diabetes Association. Diabetes Care 27 (Suppl.1): S84-S87, 2004 </li></ul></ul>3. Retinopathy In Type 1 Diabetes In Type 2 Diabetes <ul><li>Only 50% - 60% of patients with nephropathy have retinopathy. </li></ul><ul><li>Brenner and Rector. The Kidney: 1742-1743. 2000 </li></ul><ul><ul><li>Christensen et al. Kidney Int. 2000; 58: 1719–1731 </li></ul></ul>DN: Diagnostic Criteria
  19. 19. 3. Retinopathy DN: Diagnostic Criteria
  20. 20. 3. Retinopathy DN: Diagnostic Criteria
  21. 21. Higher levels of blood pressure are associated with more rapid progression of diabetic kidney disease Most patients with diabetic kidney disease are hypertensive Hypertension is both a cause and a consequence of renal disease and the kidney is both villain and victim in hypertension. Critchley JA et al. Chin Med J (Engl). 2002 Jan;115(1):129-35. 4. Hypertension DN: Diagnostic Criteria
  22. 22. 4. Hypertension DN: Diagnostic Criteria With Macroalbuminuria: >90% With Microalbuminuria: 80% At Diagnosis: 50% Type 2 With Macroalbuminuria: 65-88% With Microalbuminuria: 30-50% At Diagnosis: 20-40% Type 1
  23. 23. <ul><li>Cause: Usually renoparenchymal in origin. </li></ul><ul><li>Onset: Typically with microalbuminuria. </li></ul><ul><li>American Diabetic Association. Diab Care 2004 </li></ul>In Type 1 Diabetes <ul><li>Cause: Mainly due to insulin resistance (as a facet of MS) But may be due to underlying DN or other causes. </li></ul><ul><ul><li>American Diabetic Association. Diab Care 2004 </li></ul></ul><ul><li>Onset: Usually precedes the onset of nephropathy and even the onset of type 2 diabetes by years or decade </li></ul><ul><li>Ritz et al. J Int Med. 2001 ; 249: 215-223 </li></ul>In Type 2 Diabetes 4. Hypertension
  24. 24. <ul><li>Systolic Blood Pressure is a Stronger predictor than diastolic blood pressure for both CVD and renal complications. </li></ul><ul><ul><ul><li>National Kidney Foundation: Guideline 8. Am J Kidney Dis 43 (Suppl. 1):S142 –S159, 2004. </li></ul></ul></ul><ul><ul><ul><li>Sowers JR et al. Hypertension 37:1053 –1059, 2001. </li></ul></ul></ul>4. Hypertension Systolic Or Diastolic
  25. 25. 4. Hypertension Effect On Glomerulus Hypertension Dilatation of Afferent Arteriole Increase Intraglomerular Pressure Hyperfiltration Hemodynamically Mediated Damage Evans CT. Clin Diab. VOL. 18 NO. 1 2000
  26. 26. <ul><li>The UK Prospective Diabetes Study Group (UKPDS) concluded that: </li></ul><ul><li>“ Not only is antihypertensive treatment more effective than tight blood glucose control; but also the beneficial effect comes sooner” </li></ul><ul><li>Mogensen et al. BMJ. 1998 Sep 12;317(7160):693-4 </li></ul>4. Hypertension Strong Or The Strongest Aggravating Factor For DN <ul><li>Chinese Medical Journal 2002 : </li></ul><ul><li>Hypertension is the most important aggravating risk factor in DN. </li></ul><ul><li>Effective antihypertensive therapy is the most important strategy in preserving renal function”. </li></ul><ul><li>Critchley JA et al. Chin Med J (Engl). 2002 Jan;115(1):129-35. </li></ul>
  27. 27. 4. Hypertension Strong Or The Strongest Aggravating Factor For DN
  28. 28. <ul><li>Initially GFR is increased due to hyperfiltration. </li></ul><ul><li>Typically, SCr is normal till development of Overt DN (Macroalbuminuria). </li></ul><ul><li>Once overt DN occurs, GFR start to decrease at a rate of 1ml/min/month (variable 2-20 ml/min/year). </li></ul>5. Progressive Deterioration of RF DN: Diagnostic Criteria
  29. 29. 5. Progressive Deterioration of RF DN: Diagnostic Criteria
  30. 30. Causes that may  Urinary Albumin <ul><li>Infection </li></ul><ul><li>Fever </li></ul><ul><li>Exercise within 24 h </li></ul><ul><li>CHF </li></ul><ul><li>Marked hyperglycemia </li></ul><ul><li>Marked hypertension </li></ul><ul><li>Pyuria </li></ul><ul><li>Hematuria </li></ul><ul><li>Menstruation </li></ul><ul><li>Pregnancy </li></ul>6. Exclusion of Other Causes DN: Diagnostic Criteria
  31. 31. Lack of Retinopathy or Neuropathy Persistent Hematuria (microscopic or macroscopic) Signs or symptoms of Systemic Disease Rapidly Rising Creatinine High SCr with little or no Proteinuria F/H of Nondiabetic Renal Disease (e.g. polycystic kidney disease or Alport syndrome) Short Duration of Diabetes 6. Exclusion of Other Causes Markers of Non Diabetic Renal Diseases Indications of Renal Biopsy in Diabetes 1 2 3 4 5 6 7
  32. 32. Diabetic Nephropathy Pathogenesis of DN
  33. 33. Intra glomerular HTN Hyperperfusion Aff VD/ Eff VC Hyperfiltration Polyol Pathway Protein Kinase C GF, Cytokines(TGF-B) ROS  Gl.Hydrolic Pressure Endothelial Dysfunction Angitensin II Glucotoxicity Structural Changes Metabolic Changes Functional Changes AGEs  Renal Plasma Flow Glomerulosclerosis Thickening of GBM Mesangial Expansion Hyperglycemia Renal Hypertrophy
  34. 34. DN: Pathogenesis
  35. 35. DN: Pathogenesis
  36. 36. Diabetic Nephropathy Stages of DN
  37. 37. <30mg/day 30-300mg/day >300mg/d DN: Stages
  38. 38. Natural History of Type 1 Diabetic Nephropathy DN: Natural History
  39. 39. Susceptibility Silent Silent Incipient Overt ESRD DN: Natural History Natural History of Type 2 Diabetic Nephropathy
  40. 40. Diabetics with Macroalbuminuria are More Likely to Die than Develop ESRD C V D E A T H The United Kingdom Prospective Diabetes Study (approx. 5000 Type 2 Diabetics) Newly diagnosed, predominantly white, medically treated Adler et al. Kid Int, 2003 Elevated Serum Creatinine 19% No albuminruia 1.4% Microalbuminruia 3.0% Macroalbuminruia 4.6%
  41. 41. Diabetic Nephropathy Death Rate In Diabetic Patients on RRT 54.1
  42. 42. Causes of Death DN: Causes of Death Stroke Myocardial Infarction Heart Failure Sudden Death
  43. 43. <ul><li>Not all patients with Microalbuminuria will develop Macroalbuminuria. </li></ul><ul><li>Not all patients with Macroalbuminuria will develop ESRD. </li></ul>DN: Prognosis
  44. 44. Microalbuminuria Macroalbuminuria 80%/10-15y Macroalbuminuria ESRD 50%/ 10y 75%/ 20y Without Specific Interventions in type 1 DM Microalbuminuria Macroalbuminuria Macroalbuminuria ESRD 20%/ 20y Without Specific Interventions in type 2 DM 20-40 % American Diabetic Association. Diab Care 2004 DN: Prognosis
  45. 45. DN: Where to Meet the Patients? Susceptibility Silent Silent Incipient Overt ESRD Screening and Prevention of Type 2 Diabetes Screening and Prevention of Diabetic Nephropathy Natural History of Type 2 Diabetic Nephropathy Prevention of progression of MiA to overt DN
  46. 46. Preventive/ Pre-emptive Strategies Screening For DN Prevention Of DN
  47. 47. 1 American Diabetes Association: Nephropathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl.1): S79-S83, 2004 BP UAE Lipid At Least Annually < 150mg/dl TG < 100 mg/dl LDL > 40mg/dl HDL DN: Screening
  48. 48. DN: Screening
  49. 49. <ul><li>Screening for microalbuminuria can be performed by three methods: </li></ul><ul><ul><li>Albumin-to-Creatinine Ratio in a random spot collection </li></ul></ul><ul><ul><li>24-h Urine Collection with creatinine, allowing the simultaneous measurement of creatinine clearance </li></ul></ul><ul><ul><li>Timed (e.g., 4-h or overnight) collection. </li></ul></ul><ul><li>The first method is preferred (easy and accurate) </li></ul><ul><ul><li>First-void or other morning collections are best because of the known diurnal variation in albumin excretion </li></ul></ul><ul><ul><li>If this timing cannot be used, uniformity of timing for different collections in the same individual should be employed. </li></ul></ul><ul><li>Measurement of microalbuminuria: </li></ul><ul><ul><li>Specific assays : </li></ul></ul><ul><ul><ul><li>Radioimmunoassay </li></ul></ul></ul><ul><ul><ul><li>Enzyme-linked immunosorbent assay </li></ul></ul></ul><ul><ul><ul><li>Nephelometry </li></ul></ul></ul><ul><ul><li>Reagent tablets or dipsticks for microalbumin may be carried out, since they show acceptable sensitivity (95%) and specificity (93%) when carried out by trained personnel. </li></ul></ul><ul><ul><ul><li>All positive tests by reagent strips or tablets should be confirmed by more specific methods. </li></ul></ul></ul><ul><li>There is also marked day-to-day variability in albumin excretion, so at least two of three collections done in a 3- to 6-month period should show elevated levels before designating a patient as having microalbuminuria. </li></ul>DN: Screening
  50. 50. DN: Screening
  51. 51. Dietition Endocrinologist Physician Trained Diabetes Nurse General Practitioner Multiseciplinary Approach Prevention Of DN Requirements DN: Prevention/Preemptive St.
  52. 52. <ul><li>Familial history of HTN, cardiovascular events (1st degree relatives). </li></ul><ul><li>Hypertensive or even Small increase in systemic BP, within the normal range or loss of nocturnal dipping. </li></ul><ul><li>With Poor glycemic control: Sustained hyperglycemia HbA1c > 8.6. </li></ul><ul><li>Has Retinopathy. </li></ul><ul><li>Dyslipidemic. </li></ul><ul><li>Smoker. </li></ul><ul><li>With protein intakes greater than 20% of energy intake. </li></ul><ul><li>Has slightly elevated urinary albumin excretion: upper limit of normal. </li></ul><ul><li>Short stature or History of Low Birthweight. </li></ul><ul><li>Women using Oral contraceptive. </li></ul><ul><li>Presence of Cardiovascular risk markers. </li></ul>Target Diabetic Populations DN: Prevention/Preemptive St.
  53. 53. <ul><li>Cigarette smoking should be actively discouraged. </li></ul><ul><li>Life Style Changes : </li></ul><ul><ul><ul><li>Moderate weight loss (7% body weight) </li></ul></ul></ul><ul><ul><ul><li>Regular physical activity (150 min/week) </li></ul></ul></ul><ul><ul><ul><li>Dietary fiber (14 g fiber/1,000 kcal) and foods containing whole grains </li></ul></ul></ul><ul><ul><ul><li>Reduced intake of fat to reduce calories. </li></ul></ul></ul><ul><li>Avoidance of Oral Contraceptive. </li></ul><ul><li>Correction of CV Risk Factors. </li></ul><ul><li>Sodium Intake : High sodium intake should be avoided. </li></ul>Measures DN: Prevention/Preemptive St.
  54. 54. <ul><li>Protein Intake </li></ul><ul><ul><li>Restriction </li></ul></ul><ul><ul><ul><li>Not to exceed a protein intake of 20% of total energy. </li></ul></ul></ul><ul><ul><li>Toeller et al. Diabetologia. 1997 Oct;40(10):1219-26. </li></ul></ul><ul><ul><li>Normal Protein Diet </li></ul></ul><ul><ul><ul><li>Fish and chicken are the only source </li></ul></ul></ul><ul><ul><ul><li>Mollsten AV et al. Diabetes Care 24:805–810, 2001 </li></ul></ul></ul><ul><ul><ul><li>Gross JL et al. Diabetes Care, April 1, 2002; 25(4): 645 - 651. </li></ul></ul></ul><ul><ul><ul><li>Pecis M et al. Diabetes Care 17:665–672, 1994 </li></ul></ul></ul><ul><ul><li>Selection: Robertson et al; 2007 suggested that six months therapeutic trial of protein restriction for all patient with DKD, with continuation only in those who responded best. </li></ul></ul><ul><ul><li>Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002181. </li></ul></ul>Measures DN: Prevention/Preemptive St.
  55. 55. <ul><li>Glycaemic control should be optimised, with FBS < 6 mmol/l and/or HbA1c < 7% </li></ul><ul><li>Mentain Target BP < 130/80 </li></ul><ul><li>ACE-I / ARBs </li></ul><ul><li>Mentian Lipid Profile : </li></ul><ul><ul><ul><li>LDL<100 mg/dl (<2.6 mmol/l)     </li></ul></ul></ul><ul><ul><ul><li>Triglycerides<150 mg/dl (<1.7 mmol/l)     </li></ul></ul></ul><ul><ul><ul><li>HDL>40 mg/dl (>1.0 mmol/l) </li></ul></ul></ul>Measures DN: Prevention/Preemptive St.
  56. 56. Treatment of Overt DN
  57. 57. The Renal Injury Triad Angiotensin II Proteinuria Hypertension In Diabetes Smoking Hyperlipidemia Hyperglycemia Dietary protein
  58. 58. <ul><li>Tight Control of BP: </li></ul><ul><ul><ul><li>Proteinuria < 1 g/day  < 130/ 80 </li></ul></ul></ul><ul><ul><ul><li>Proteinuria > 1 g/day  < 125/75 </li></ul></ul></ul><ul><li>Tight Glycemic Control: </li></ul><ul><ul><ul><li>FPG < 6 mmol/l </li></ul></ul></ul><ul><ul><ul><li>HbA1c < 6.5-7 </li></ul></ul></ul><ul><li>Blockage of RAS and control of P roteinuria: </li></ul><ul><ul><ul><li>If there is microalbuminuria: ACE-I and ARBs in type 1 and type 2. </li></ul></ul></ul><ul><ul><ul><li>If there is macroalbuminuria: </li></ul></ul></ul><ul><ul><ul><ul><li>ACE-I preferred in type 1. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>ARBs preferred in type 2. </li></ul></ul></ul></ul>DN: Treatment
  59. 59. <ul><ul><ul><li>Either agent can be used as alternative agent if the preferred can not be used. </li></ul></ul></ul><ul><ul><ul><li>Use moderate to high doses. </li></ul></ul></ul><ul><ul><ul><li>If proteinuria > 1g/day: </li></ul></ul></ul><ul><ul><ul><ul><li>Maxmise the dose of ACE-I or ARBs. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Use combination of both. </li></ul></ul></ul></ul><ul><ul><ul><li>For control of Proteinuria: </li></ul></ul></ul><ul><ul><ul><ul><li>If ACE-I or ARBs not tolerated, Use NDCCBs. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>DCCBs is not proved to be effective. </li></ul></ul></ul></ul><ul><li>Multiple Risk Factors Intervention: </li></ul><ul><ul><ul><li>Control of Dyslipidemia: </li></ul></ul></ul><ul><ul><ul><ul><li>LDL<100 mg/dl (<2.6 mmol/l), < 70 mg/dl if there is CVD.      </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Triglycerides<150 mg/dl (<1.7 mmol/l)     </li></ul></ul></ul></ul><ul><ul><ul><ul><li>HDL>40 mg/dl (>1.0 mmol/l) </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Total Cholesterol < 175 mg/dl </li></ul></ul></ul></ul><ul><ul><ul><li>Smoking Cessation </li></ul></ul></ul>DN: Treatment
  60. 60. <ul><ul><ul><li>Diet control: </li></ul></ul></ul><ul><ul><ul><ul><li>Protein </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Restriction: 0.8-1mg/kg bw (controversial). </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Normal Protein with Chicken and fish the only source of protein. </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><li>Fiber (14 g fiber/1,000 kcal) and foods containing whole grains. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Fat: Reduced intake of fat. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Salt: Restriction to 2.4g/day. </li></ul></ul></ul></ul><ul><ul><ul><li>Life Style Changes: </li></ul></ul></ul><ul><ul><ul><ul><li>BMI < 25 kg/m 2 . </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Regular physical activity (150 min/week). </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Moderation of Alcohol. </li></ul></ul></ul></ul><ul><li>Aspirin: 81 mg/day as preventive strategy in high risk Type 2 diabetic patients. </li></ul>DN: Treatment
  61. 61. <ul><li>Monitor Serum Potassium: </li></ul><ul><ul><ul><li>ACE-I or ARBs may cause Hyperkalemia: </li></ul></ul></ul><ul><ul><ul><ul><li>Avoid other medications that cause hyperkalemia (K suppl, NSAIDs, Cox2 inhibitors, K sparing diuretics). </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Evaluate causes of hyperkalemia. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Treat hyperkalemia with diuretics. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Continuo ACE-I or ARBs if K < 5.5 mmol/l </li></ul></ul></ul></ul><ul><ul><ul><li>Diuretics may cause hypokalemia: </li></ul></ul></ul><ul><ul><ul><ul><li>Evaluate causes of hypokalemia. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Treat hypokalemia with caution in CKD. </li></ul></ul></ul></ul><ul><li>Monitor GFR </li></ul><ul><ul><ul><ul><li>If GFR >30% within 4 weeks, evaluate. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Continuo ACE-I or ARBs if GFR < 30% from baseline over 4 months. </li></ul></ul></ul></ul>DN: Treatment
  62. 62. <ul><li>Avoidance of Nephrotoxicity: </li></ul><ul><ul><ul><li>Nephrotoxic: </li></ul></ul></ul><ul><ul><ul><ul><li>Radiocontrast agents – low ionic agents, avoid dehydration </li></ul></ul></ul></ul><ul><ul><ul><ul><li>NSAID* – use paracetamol </li></ul></ul></ul></ul><ul><ul><ul><li>Needs adjustment if GFR is reduced </li></ul></ul></ul><ul><ul><ul><ul><li>Allopurinol – 100 mg/day per 30 mL/min of GFR </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Digoxin – check levels </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Sulphonamides – half dosage if GFR is <30 mL/min </li></ul></ul></ul></ul><ul><ul><ul><li>Not used if GFR <30 mL/min </li></ul></ul></ul><ul><ul><ul><ul><li>Some hypoglycaemics – glibenclamide, glimepiride, metformin </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Potassium sparing diuretics – amiloride, triamterene, spironolactone. </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Tetracyclines </li></ul></ul></ul></ul>DN: Treatment
  63. 63. <ul><li>Continued Surveillance of Proteinuria: to assess both response to therapy and progression of disease is recommended. </li></ul>DN: Treatment
  64. 64. <ul><li>High doses of thiamine and its derivate benfotiamine: retard the development of microalbuminuria in experimental diabetic nephropathy, probably due to decreased activation of protein kinase C, decreased protein glycation, and oxidative stress. </li></ul><ul><li>ALT-711 (cross-link breaker of the advanced glycation end products) : has been shown to result in a significant reduction in UAE, blood pressure, and renal lesions in experimental diabetes. </li></ul>DN: Novel Therapeutic Strategies
  65. 65. <ul><li>Protein kinase C ß inhibitor (ruboxistaurin): normalized GFR, decreased albumin excretion rate, and ameliorated glomerular lesions in diabetic rodents. </li></ul><ul><li>Sulodexide (a glycosaminoglycan): significantly reduced albuminuria in micro- or macroalbuminuric type 1 and type 2 diabetic patients. </li></ul><ul><li>Pimagedine (second-generation inhibitor of advanced glycation end products): reduced urinary protein excretion and the decline in GFR in proteinuric type 1 diabetic patients in a randomized, placebo-controlled study. </li></ul>DN: Novel Therapeutic Strategies
  66. 66. Referrences <ul><li>Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ: Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52:2110–2120, 2003. </li></ul><ul><li>Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762–1764, 2003. </li></ul><ul><li>Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE: Protein kinase C ß inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512–518, 2003 </li></ul><ul><li>Gambaro G, Kinalska I, Oksa A, Pont’uch P, Hertlova M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicova J, Skrha J, Taton J, Grzeszczak W, Crepaldi G: Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13:1615–1625, 2002. </li></ul><ul><li>Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, Spinowitz BS, Whittier FC, Wuerth JP: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32–40, 2004. </li></ul>
  67. 67. <ul><li>Blood pressure should be measured at every routine diabetes visit. </li></ul><ul><ul><li>Patients found to have systolic blood pressure >130 mmHg or diastolic blood pressure >80 mmHg should have blood pressure confirmed on a separate day. </li></ul></ul><ul><ul><li>Orthostatic measurement of blood pressure should be performed to assess for the presence of autonomic neuropathy. </li></ul></ul>Antihypertensive Drugs in DKD
  68. 68. <ul><li>Target BP <130/80 mmHg and < 125/75 mmHg if proteinuria > 1g/day. </li></ul><ul><li>If BP 130–139 / 80–89 mmHg   lifestyle/ behavioural therapy alone for a maximum of 3 months  If targets are not achieved, pharmacological therapy should be started. </li></ul>Antihypertensive Drugs in DKD
  69. 69. <ul><li>If BP ≥140/90 mmHg  Drug therapy in addition to lifestyle/behavioral therapy. </li></ul><ul><li>Antihypertensive Drugs in Diabetes </li></ul><ul><ul><ul><li>First and second lines agents: </li></ul></ul></ul>Antihypertensive Drugs in DKD
  70. 70. <ul><ul><ul><li>DKD with or without hypertension: ACE-I, ARBs. </li></ul></ul></ul><ul><ul><ul><li>DKD (either type 1 and type 2) with MiA  ACE-I, ARBs. </li></ul></ul></ul><ul><ul><ul><li>DKD (type 1 diabetes) with MaA  ACE-I. </li></ul></ul></ul><ul><ul><ul><li>DKD (type 2 diabetes) with MaA  ARBs </li></ul></ul></ul>Antihypertensive Drugs in DKD
  71. 71. <ul><ul><ul><li>Drugs that has antiproteinuric effect than other antihypertensives: </li></ul></ul></ul><ul><ul><ul><ul><li>ACE-I </li></ul></ul></ul></ul><ul><ul><ul><ul><li>ARBs </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Nd CCBs </li></ul></ul></ul></ul><ul><ul><ul><ul><li>BB. </li></ul></ul></ul></ul><ul><ul><ul><li>DCCBs are less effective in slowing progression of DKD and if needed, should combined with ACE-I or ARBs. </li></ul></ul></ul>Antihypertensive Drugs in DKD
  72. 72. <ul><li>Spironolactone added to ACE inhibitor or ARB therapy provides additional reno- and CV protective benefits in patients with diabetic nephropathy. </li></ul><ul><li> Israili et al. Am J Ther. 2007 Jul-Aug;14(4):386-402. </li></ul>Role of Spironolactone
  73. 73. <ul><li>Addition of spironolactone (25-50 mg OD) to an ACE inhibitor or AngII receptor blocker is associated with a marked and sustained antiproteinuric effect, which in part relates to the more pronounced reduction in GFR. </li></ul><ul><li>van den Meiracker et al. J Hypertens. 2006 Nov;24(11):2285-92. </li></ul>Role of Spironolactone
  74. 74. Role of Spironolactone
  75. 75. Role of Spironolactone
  76. 76. THANKS Dr. Mohamed Alamin